Why Retrophin Inc. Shares Blasted Off

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Retrophin (NASDAQ: RTRX  ) , a biopharmaceutical company focused on developing therapies to treat rare disease, soared as much as 31% after announcing a double-dose of good news after the closing bell last night.

So what: First, Retrophin announced that it had arranged for $80 million worth of term loans. Generally speaking debt issuance is frowned upon, however, both of its offerings (two $40 million loans) allow for the conversion of warrants or notes into common stock at a premium to yesterday's closing price. Its $40 million senior secured loan issued the lender 300,000 warrants with an exercise price of $13.93, while its $40 million senior convertible notes offer an initial conversion price of $17.41 per share. Simply put, these higher conversion prices imply expected upside in the company over the coming years.

In addition, Retrophin entered into a U.S. license agreement with privately held Mission Pharmacal Co. for the marketing rights to Thiola, a treatment for cystinuria, a rare genetic cysteine transport disorder. As Martin Shkreli, founder and CEO of Retrophin commented, "Thiola adds another commercial product to our portfolio and is a strategic fit with our focus on rare disease, particularly renal disease." Financial terms of the licensing agreement were not disclosed.

Now what: Like I said, it was a double-dose of good news for Retrophin. First, the company gets financing to continue researching serious and rare disease therapies, all while ensuring that shareholders don't get diluted by a share offering. Also, the addition of Thiola should immediately impact Retrophin's top-line and help reduce its cash burn, which prior to last night's licensing agreement announcement looked as if it would top $30 million in 2015. Make no mistake about it; these are both positive developments for Retrophin. As for me, I'm still not overly excited by its pipeline and would prefer to remain on the sidelines until Retrophin gets a lot closer to profitability.

Retrophin shares may have soared today, but they'll probably have a tough time keeping up with this top stock going forward
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2977534, ~/Articles/ArticleHandler.aspx, 9/19/2014 12:05:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement